Beta Bionics, Inc.
No enriched coverage for $BBNX in the last 7 days.
Beta Bionics (BBNX) rose 6.8% to $25.53 after partnering with Senseonics to integrate its insulin delivery systems with Senseonics' Eversence 365 sensor. The first product is expected in Q4. CEO Sean Saint highlighted the expanded reach for diabetes management.
Ultragenyx (RARE) gained FDA approval for FAYUVI, a treatment for Sanfilippo syndrome Type A, closing at $14.50, up 12.58%. Nuvation Bio (NUVB) expanded IBTROZI's label with new lung cancer data, closing at $6.07, up 5.02%. Bayer (BAYRY) won FDA approval for Kerendia in type 1 diabetes-related CKD, closing at $14.13, up 0.57%. Biogen (BIIB) and Eisai (ESALY.PK) received Japan approval for LEQEMBI Pen, closing at $219.05, up 1.41%. Telix (TLX) got FDA approval for Pixclara, a PET imaging agent fo
Beta Bionics completed a $172.5 million public offering. The company's stock has seen a 5-day change of 21.43 USD, a 1st Jan change of -3.38%, and a year-to-date change of +29.17%. BofA Securities recently adjusted its price target to $18 from $15.50.
Recent BBNX coverage spans corporate actions, regulation and financial news.
In the last 30 days, BBNX insiders filed 6 SEC Form 4 transactions — no purchases and 6 sales ($1.6M). The most active reporter was Hopman Mark, Chief Commercial Officer, with 3 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
The collaboration expands Beta Bionics' product ecosystem and may boost sales in the diabetes market.
New device entry could diversify revenue.
Beta Bionics completed a $172.5 million public offering. The company's stock has seen a 5-day change of 21.43 USD, a 1st Jan change of -3.38%, and a year-to-date change of +29.17%. BofA Securities recently adjusted its price target to $18 from $15.50.
Insider sale of roughly $620K may signal limited confidence from a senior officer.
The capital raise will dilute existing shareholders but provides cash for Mint commercialization and manufacturing expansion.
AlphAI scores every news story that mentions BBNX with an AI model for sentiment and relevance, and aggregates insider trades from Beta Bionics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Beta Bionics (BBNX) rose 6.8% to $25.53 after partnering with Senseonics to integrate its insulin delivery systems with Senseonics' Eversence 365 sensor. The first product is expected in Q4. CEO Sean Saint highlighted the expanded reach for diabetes management.
1 min readUltragenyx (RARE) gained FDA approval for FAYUVI, a treatment for Sanfilippo syndrome Type A, closing at $14.50, up 12.58%. Nuvation Bio (NUVB) expanded IBTROZI's label with new lung cancer data, closing at $6.07, up 5.02%. Bayer (BAYRY) won FDA approval for Kerendia in type 1 diabetes-related CKD, closing at $14.13, up 0.57%. Biogen (BIIB) and Eisai (ESALY.PK) received Japan approval for LEQEMBI Pen, closing at $219.05, up 1.41%. Telix (TLX) got FDA approval for Pixclara, a PET imaging agent fo
3 min readBeta Bionics completed a $172.5 million public offering. The company's stock has seen a 5-day change of 21.43 USD, a 1st Jan change of -3.38%, and a year-to-date change of +29.17%. BofA Securities recently adjusted its price target to $18 from $15.50.
1 min readHopman Mark (Chief Commercial Officer) sold 30,779 shares of Beta Bionics, Inc. (BBNX) at $20.13 ($0.62M total) on 2026-09-16 under a Rule 10b5-1 trading plan.
1 min readBeta Bionics (BBNX) raised $172.5M in a stock offering, selling 7.65M shares at $17.25 each. Underwriters exercised an option for 1.3M more shares. Proceeds will support Mint commercialization, manufacturing, and R&D. J.P. Morgan and others managed the offering.
2 min readBeta Bionics (BBNX) received FDA clearance for its Mint patch pump, expanding its insulin delivery portfolio. The company also announced a next-gen 3D Intelligence algorithm under review. BBNX stock surged 15% on the news, despite a 27.2% YTD decline. The FDA clearance opens access to the growing patch pump market and may improve long-term margins.
2 min readBeta Bionics received FDA clearance for its Mint tubeless insulin patch pump, planning a U.S. launch in early 2027. The company expects 40% of insured Americans to have pharmacy coverage at launch, rising to 50% within a year. Beta Bionics lowered its 2026 revenue forecast to $121M-$126M, citing potential deferrals as customers wait for Mint. The pump will compete with Insulet's dominant patch pump and Medtronic's upcoming submission.
2 min readBeta Bionics (BBNX) priced a public offering of 7.65 million shares at $17.25 each and pre-funded warrants for 1.04 million shares at $17.2499, raising $150 million. The deal, expected to close by September 17, 2026, includes a 30-day over-allotment option. Latham & Watkins advised the underwriters.
1 min readBeta Bionics (BBNX) stock rose 5.93% to $20.37 after announcing a public offering expected to generate $150M in gross proceeds. The offering includes 7.65M common shares and warrants. Proceeds will fund corporate purposes, including commercialization and R&D.
1 min readU.S. stock futures rose Wednesday. Beta Bionics (BBNX) fell 7.1% to $17.87 after announcing a public stock offering. Other decliners included J.B. Hunt Transport (JBHT), down 9.6% to $246.90, and Akso Health (AHG), down 10% to $0.72.
1 min read
